ABL1 and pancreatitis: Ponatinib holds the promise because it is a potent inhibitor not only for native BCR-ABL but also for all known BCR-ABL mutants, including BCR-ABL T315I23, however, its adverse effect including myelosuppression and pancreatitis limits its wide use24.